According to the American Cancer Association [13], there are currently four major breast tumor molecular subtypes with prognostic differences on patients outcome based on expression or not of specific biological markers: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) [Table 1]. Here, ERBB2 is linked to breast neoplasm.